Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
How tertiary lymphoid structures predict pembrolizumab response in soft-tissue sarcoma — and why plasma cells matter
Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
Can trabectedin plus durvalumab help platinum-resistant ovarian carcinoma and soft tissue sarcoma?
How CD95 keeps NF-κB switched off in triple-negative breast cancer — and what its loss unleashes
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
